1620 results about "Drug development" patented technology

A scalable platform for orchestrating networks of specialized AI multi-agent networks that enables secure collaboration through token-based protocols and real-time result streaming with advanced dynamic chain-of-thought pruning. The central orchestration engine manages domain-specific agents, implementing sophisticated multi-branch reasoning with contribution-estimation layers that evaluate each agent's utility using Shapley value-inspired metrics. The system employs information-theoretic and gradient-based surprise metric to guide memory updates and dynamic reasoning expansion, preventing local minima stagnation while preserving valuable insights through adaptive forgetting mechanisms. The platform unifies Monte Carlo tree search with contribution-aware estimation to detect high-synergy expert combinations while maintaining privacy through partial data approaches. It scales across distributed computing environments, enabling complex collaborative tasks like materials discovery, product engineering and manufacturing process design, biomedical research, and drug development. The system supports multi-party economic rewards through systematic contribution effort, cost and importance tracking, while standardized interfaces manage security, privacy, and policy constraints across heterogeneous agents.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The invention relates to the field of bioinformatics and drug development, and discloses an efficient siRNA effectiveness prediction method and system based on an XGBOOST algorithm. The method comprises the following steps: acquiring a training data set containing siRNA sequence information, chemical modification information and corresponding validity data; carrying out cleaning, feature extraction and data balance processing on the data; training the prediction model by using an XGBOOST algorithm, and optimizing hyper-parameters; performing model evaluation and optimization through cross validation; a new siRNA sequence is input for effectiveness prediction; explaining a prediction result by using an SHAP value analysis technology; the actual interference efficiency of the efficient siRNA sequence is verified through an in-vitro cell experiment, and the model is further optimized based on an experiment result. According to the method, the accuracy and efficiency of siRNA effectiveness prediction are improved, the influence of chemical modification is comprehensively considered, the problem of data imbalance is solved, the model interpretation is enhanced, and the calculation efficiency is remarkably improved.

The invention relates to an inverse synthesis route planning method and system based on a multi-modal large model, and belongs to the technical field of chemical synthesis and artificial intelligence crossing. The method comprises the following specific steps: firstly, extracting three-dimensional molecular structure characteristics of a target product through a molecular encoder, and aligning the three-dimensional molecular structure characteristics with text modals of molecules; secondly, reasoning a possible reaction mechanism and a reaction type, and reducing an inverse synthesis search space; secondly, splitting a target product into reasonable synthesis subunits through structured marking and vocabulary expansion, data-driven atomic assignment learning and reaction center recognition and activity prediction; finally, SMILES representations and reaction paths of the reactants are generated. According to the method, the accuracy and interpretability of inverse synthesis path planning can be improved, and a new technical means is provided for automation and intellectualization in the fields of new drug development, material design and the like.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The invention provides a solvent compound crystal which is formed by rosmeltirol and a 1, 4-dioxane solvent, and the molecular formula of the solvent compound crystal is C17H12Cl2N6O4.C4H8O2. The preparation process of the crystal form is simple, the operation is simple and convenient, the quality index of the obtained crystal form is basically kept unchanged in a stability acceleration experiment, the crystal form has good stability and is easy to store in the production circulation process, a good choice is provided for preparation of a medicinal preparation of the crystal form, and the crystal form has very important significance for medicine development.

The invention relates to the technical field of metabolite detection, in particular to a high-flux metabolite detection method and application thereof. According to the detection method, metabolites in a biological sample to be detected are detected by using a liquid chromatography-mass spectrometry technology, wherein mass spectrometry is quadrupole electrostatic field orbitrap high-resolution and triple quadrupole mass spectrometry; the mass spectrum conditions of the MRM ion pair are as follows: acquiring data in an NFSWI-DDA, NFSWI-DIA or DIA mode in a positive and negative ion mode, and acquiring and annotating the MRM ion pair; the MRM list is transited to triple quadrupole mass spectrometry, and the mass spectrometry conditions of the triple quadrupole mass spectrometry include verification and detection of MRM ion pairs in positive and negative ion modes. The detection method can meet the requirements of precise medical research on metabolite coverage rate, quantitative stability and detection flux, can be used for semi-quantitative and quantitative combined detection of metabolites in various biological samples, has applicability, and can provide technical support for disease diagnosis, drug development and biomarker discovery.

The invention belongs to the technical field of drug screening, and provides a multi-target drug screening and optimizing method based on machine learning, which comprises the following steps: S1, carrying out feature screening on compound molecular descriptors by utilizing a machine learning algorithm, and determining the molecular descriptor which has the most significant influence on biological activity; s2, constructing a quantitative structure-activity relation model, and predicting the biological activity of the compound; s3, based on a multi-objective optimization algorithm, combining absorption, distribution, metabolism, excretion and toxicity properties of the compound; according to the method, feature screening is carried out on compound molecule descriptors by utilizing a machine learning algorithm, a QSAR model is constructed to predict the biological activity, ADMET property classification prediction is combined, the biological activity, ADMET properties and pharmacokinetic characteristics of drugs are comprehensively considered, and the accuracy and accuracy of drug activity prediction are improved. The method can efficiently and accurately screen and optimize drug candidate compounds with potential drug effects and good pharmacokinetic characteristics, so that the success rate of drug research and development is increased, and the research and development cost and time are reduced.

The invention relates to the technical field of computer-aided drug research and development, and provides an antibacterial peptide function recognition optimization method and system based on deep learning and LLM. Systematic innovation is performed in multiple links such as feature extraction, data generation and reasoning verification by introducing a fusion mechanism of a large language model and a deep learning model; and the accuracy and robustness of antibacterial peptide function prediction are obviously improved. On one hand, a strict feature extraction process and a structured cue word template are constructed, sequence information and physicochemical property indexes of the antibacterial peptide and a prediction result of a deep learning model can be effectively integrated, and the prediction result is reasonably corrected and optimized through the reasoning ability and knowledge verification mechanism of a large language model. The misjudgment risk of a traditional deep learning method under the condition of insufficient samples or incomplete features is effectively reduced, and the prediction accuracy and stability are remarkably improved.

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.

The invention provides a bispecific antibody targeting CD3 and MICA and an application of the bispecific antibody. The present invention relates to a conjugate comprising: a first antigen binding region comprising an anti-CD3 antibody or an antigen binding fragment thereof; the present invention relates to an anti-CD3 antibody or an antigen-binding fragment thereof, comprising a first antigen-binding region having MICA binding activity, a second antigen-binding region having MICA binding activity, the anti-CD3 antibody or the antigen-binding fragment thereof comprising a first heavy chain variable region having a specific CDRs amino acid sequence and a first light chain variable region. The bispecific antibody disclosed by the invention can be combined with CD3 and MICA so as to promote T cell activation, secrete cell factors and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, so that the bispecific antibody has good anti-cancer activity; moreover, the bispecific antibody has reduced proinflammatory cytokine secretion promotion performance and T cell activation promotion performance, is higher in safety, and has good clinical application value and drug development value.

The invention discloses a multi-dimensional screening method for protein design based on a lexicographical order optimization strategy, and belongs to the field of biotechnology and synthetic biology. The method comprises the following steps: predicting a three-dimensional structure of a compound of a target protein and a ligand to construct a three-dimensional skeleton model of the target protein; generating a functional adaptive amino acid sequence; and adopting multi-dimensional screening indexes, including structure prediction precision, thermodynamic stability evaluation, thermal stability analysis and physicochemical property calculation, and performing priority ranking and hierarchical screening on candidate sequences in combination with a lexicographical order optimization algorithm. Through strict priority-driven multi-objective optimization, the design efficiency and success rate are remarkably improved, the number of experimental verification times is reduced, and the method is suitable for the fields of drug development, industrial enzyme engineering, gene therapy and the like and has important application value.

The present invention discloses the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs, and innovative applications in the field of liver cancer treatment, specifically to the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs. The present invention adopts lentiviral transfection technology to synthesize miR‑11085‑5p in vitro, and introduce it into liver cancer cells, and effectively induce liver cancer cells to undergo ferroptosis by precisely regulating the key signaling pathway of intracellular AMPKα / Nrf2, significantly inhibiting its proliferation activity. Therefore, for the disadvantages of low efficiency, large side effects and easy recurrence and metastasis of existing treatment methods for liver cancer, the miR‑11085‑5p provided by the present invention may become a biological preparation for the treatment of liver cancer, with potential drug development value, and provide a new solution for the treatment of liver cancer.

The invention discloses an enzyme response type KRAS targeted protein degradation chimera as well as a preparation method and application thereof, and belongs to the technical field of tumor targeted therapy. The enzyme response type KRAS targeted protein degradation chimera disclosed by the invention is obtained by covalently linking three parts, namely a KRAS targeted protein degradation chimera, an enzyme response type amino acid sequence and a cell penetrating peptide amino acid sequence, wherein the KRAS targeted protein degradation chimera is obtained by linking a KRAS targeted peptide and a VHL E3 ligase ligand through succinic acid. The enzyme response type KRAS targeted protein degradation chimera releases the KRAS targeted protein degradation chimera under the action of ATG4 enzyme shearing, and shows a relatively strong lung cancer resisting effect in vitro and in vivo. The invention has significant advantages in the aspect of antitumor drugs, and opens up a new field for the development of targeted protein degradation chimera drugs. Enzyme response type KRAS targeted protein degradation chimera molecular structural formula as follows: # imgabs0 #

The invention belongs to the technical field of biological medicines, and particularly relates to a sperm injury repair model and an establishment method thereof. Comprising the following steps: step 1, establishing a sperm lead poisoning model; and 2, establishing a lead poisoning sperm repair model. The method for establishing the lead poisoning sperm repair model in the step 2 comprises the following steps: (1) preparing a preparation for optimizing sperm functions in an extracellular vesicle way; (2) repairing the damaged sperms by using the preparation for optimizing the sperm function through the extracellular vesicles; and (3) detecting the activity of the repaired sperms. In the invention, by establishing a sperm injury repair model and adopting an extracellular vesicle modification technology, the key functional protein is introduced into the extracellular vesicle, and the method has important significance on auxiliary researches such as development and research of related drugs for improving sperm injury and improving sperm motility of asthenospermia patients in vitro.

The invention belongs to the technical field of biological medicines, and particularly relates to application of oxibenzophenone in preparation of a medicine for treating pathological cardiac hypertrophy and / or heart failure. Research results in myocardial cells of primary newborn rats show that Exibenzophenone can inhibit pathological hypertrophy of myocardial cells induced by phenylephrine (PE). Animal experiments show that the epoxybenzophenone can improve cardiac dysfunction induced by aortic arch constriction (TAC) and reduce cardiac hypertrophy and cardiac tissue fibrosis. The invention provides a new drug research and development approach and a drug action target for treating pathological cardiac hypertrophy and heart failure, and has very important medicinal value.

The invention relates to a polypeptide NbG7-4 capable of identifying and neutralizing SFTSV, which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody NbG7-4 is constructed; meanwhile, the curative effect of the NbG7-4 in treating the SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention belongs to the field of preparation of medical intermediates, and particularly relates to a preparation method of an On-DNA sulfinic acid structure compound. The method for preparing the On-DNA sulfinic acid structure compound comprises a step of oxidizing On-DNA thiol (phenol) into the On-DNA sulfinic acid structure compound under alkaline and heating or illumination conditions, a solvent used in the reaction step is a mixed solution of water, dimethyl sulfoxide, N, N-dimethylformamide, acetonitrile, ethanol or tetrahydrofuran, the reaction temperature is not more than 80 DEG C, and the reaction time is not more than 2 hours. And the illumination wavelength ranges from 365 nanometers to 535 nanometers. The On-DNA sulfinic acid structure compound obtained in the invention can be directly used for constructing a structure compound with a sulfonyl group, the reaction condition is mild and convenient, a new method and a new idea are provided for construction of a DNA coding compound library, and the On-DNA sulfinic acid structure compound has a very good application prospect in lead drug development.

The present application belongs to the field of medicines, and particularly relates to a pharmaceutical cocrystal of finerenone and maleic acid, and a preparation method therefor. The pharmaceutical cocrystal of finerenone and maleic acid prepared in the present application has the advantages of high purity, suitable solubility, good stability, etc. and is suitable for new drug development and industrial production. The method for preparing the pharmaceutical cocrystal of finerenone and maleic acid provided in the present application has the advantages of simple process route and low cost, and is suitable for industrial production.

The invention belongs to the technical field of antibacterial active microorganisms, and particularly relates to a strain of diffusion carbon pad bacteria LUCF 4343-3, a bacterial agent and application of the bacterial agent in preparation of an antibacterial preparation. According to the invention, an endophytic fungus strain with remarkable antibacterial potential is successfully separated from Parmotrema, and the endophytic fungus strain is identified as diffusion carbon pad fungus LUCF 4343-3. Experiments show that an ethyl acetate extract of the strain shows a good inhibition effect on various clinical common pathogenic bacteria, including gram-positive bacteria (staphylococcus aureus and enterococcus faecalis), gram-negative bacteria (pseudomonas aeruginosa), fungi (candida albicans and candida glabrata) and the like; the discovery provides an important basis for the application of the strain in the development of novel broad-spectrum antibacterial drugs.

The invention belongs to the technical field of microbial medicine, and provides a primary multidrug resistance human far-end bile duct cancer cell line CBC3T-6 Homo sapiens and application thereof.The human far-end bile duct cancer cell line CBC3T-6 Homo sapiens is separated from differentiated adenocarcinoma in a far-end bile duct, the human far-end bile duct cancer cell line CBC3T-6 Homo sapiens is already subcultured to 50 generations at present, the long-term in-vitro culture character is stable, and on the premise that the biological characteristics of bile duct cancer are reserved, the human far-end bile duct cancer cell line CBC3T-6 Homo sapiens can be used for preparing the primary multidrug resistance human far-end bile duct cancer cell line CBC3T-6 Homo sapiens. The compound has the characteristics of short multiplication time, high mouse subcutaneous tumor formation rate and the like, and has different degrees of drug resistance to gemcitabine, 5-fluorouracil, oxaliplatin and cis-platinum in first-line anti-cancer drugs for bile duct cancer. The method not only enriches an extrahepatic bile duct cancer cell bank, provides a new cell model for basic research and clinical drug research and development of bile duct cancer, but also provides powerful scientific research data for research developed based on the genetic background of Chinese population. Therefore, the primary multidrug resistant cell line has higher scientific research and clinical application values.

The invention belongs to the technical field of biology, and particularly relates to an immortalized alpaca kidney cell line and a construction method and application thereof. The immortalized alpaca kidney cell line disclosed by the invention is named as immortalized alpaca kidney cells (Alpaca kidney cells) BNalpaca 1.0, and the preservation number of the immortalized alpaca kidney cell line is CGMCC (China General Microbiological Culture Collection Center) No.46058. The construction method of the immortalized alpaca kidney cell line comprises the following steps: extracting and culturing alpaca primary kidney cells; infecting alpaca primary kidney cells by using SV40 large T antigen immortalized lentivirus; carrying out resistance screening on the immortalized alpaca kidney cells; carrying out alpaca kidney cell immortalized cell detection and identification; and obtaining the immortalized alpaca kidney cell line. The immortalized alpaca kidney cell constructed by the invention has the advantages of simple culture, repeated passage, good homogeneity, high expression quantity of constructed exogenous genes and the like, and provides a more powerful tool cell for research on alpaca immunity; the immortalized alpaca kidney cell line provides a new tool for virus infection mechanism, drug in-vitro function detection and antibody drug development and screening.

The application provides a Huangdache oligosaccharide with GLP-1 agonist activity and application thereof, and belongs to the technical field of medicines. 3 The oligosaccharide component ELYP-3 has a molecular weight of 3.2*10 3 Da, and the molar ratio of monosaccharides is rhamnose:galacturonic acid:glucose:galactose:arabinose = 1:32.42:45.37:9.11:6.54. The Huangdache oligosaccharide fragment obtained by glycosidase degradation has significant hypoglycemic and weight loss activities, the preparation process is simple, specific and green, and provides scientific basis and theoretical support for the development of natural GLP-1 agonists. Meanwhile, the functional oligosaccharide provides a wide application prospect for the development of medicines with blood glucose regulation.

The invention relates to a nano antibody Nb3-18 capable of identifying and neutralizing SFTSV (swine fever with thrombocytopenia syndrome), which comprises three complementary determining regions CDR1-3, and the sequences of the three complementary determining regions CDR1-3 are respectively shown as SEQ ID NO: 1-3. Nanometer antibody drug development and diagnostic kit research and development are carried out on SFTSV which is high in fatality rate but lacks effective vaccines and specific antiviral drugs, the nanometer antibody VHH which is specifically combined with GN is screened through the platform technology of preparing GN protein, inactivating viruses, immunizing alpaca, displaying nanometer monoclonal antibodies through a phage library and the like, the CDR sequence of the nanometer antibody VHH is identified, and the SFTSV with the high fatality rate is obtained. A humanized antibody Nb3-18 is constructed; meanwhile, the curative effect of Nb3-18 in treating SFTSV infection is evaluated at the in-vitro cell level. The invention provides a potential nano antibody new drug for clinical treatment of SFTSV, and also provides a corresponding detection kit for diagnosis of SFTSV.

The invention belongs to the technical field of biological medicine, and particularly discloses an artificial valve tissue calcification model and a preparation method and application thereof. The preparation method comprises the following steps: providing human valvular interstitial cells; the method comprises the following steps: providing a hydrogel system, wherein the hydrogel system comprises type I collagen, fibrinogen and Matrigel matrigel; constructing an engineered heart valve tissue strip by taking the hydrogel system as a skeleton structure between valve interstitial cells; and culturing the engineered heart valve tissue strip by using a calcification induction culture solution, so that the valve tissue generates a calcification phenotype. The model provided by the invention can generate a valve calcification phenotype which is similar to that after human heart valve calcification and is represented by valve interstitial cell activation, extracellular matrix remodeling such as collagen mass secretion and calcium deposition region generation. The model provided by the invention is low in cost, can be produced in batches, meets the research on the pathogenesis of extracorporeal valve calcification, and makes up for the dilemma that no artificial valve calcification model is available for drug research and development at present.

The present invention provides a tetrazole compound, a pharmaceutical composition thereof and a use thereof. The compound of the present invention has a brand-new structure, a low clearance rate, high plasma exposure, good oral bioavailability, and good pharmacokinetic properties, and is conducive to drug development. The compound of the present invention or a pharmaceutically acceptable salt thereof can be used for preventing and / or treating pain, including neuropathic pain, etc.

The invention belongs to the technical field of drug development, and particularly relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of drugs for treating nervous system diseases. The invention aims to provide a medicine which has small toxic and side effects and can target SLC11A2 to treat or improve nerve cell injury. According to the technical scheme, the invention relates to application of 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide in preparation of a medicine for treating nervous system diseases. It is proved that the compound 2-fluoro-N-(2-(4-methyl-2-(m-tolyl) thiazole-5-yl) ethyl) benzenesulfonamide is small in toxic and side effect, and nerve cell damage can be protected or improved by targeting SLC11A2; and a new choice is provided for treating or improving nerve cell injury.

The invention discloses a method for screening a non-natural nucleic acid aptamer of targeted thrombin based on streptavidin magnetic beads and application, and belongs to the technical field of biology. According to the method, an initial screening library is efficiently constructed through a primer extension technology, and a chemical modification SELEX technical process is simplified; a streptavidin magnetic bead separation technology is introduced, so that the screening specificity and efficiency are improved, the screening period is remarkably shortened, and the cost is reduced; by selecting non-natural nucleic acid modification sites and adopting a strategy of combining reverse screening and forward screening, high specificity and affinity of the aptamer are ensured, and limitation of an existing screening method is overcome; the screened non-natural nucleic acid aptamer shows high affinity and excellent stability, the aptamer with a specific structure and function is successfully obtained by optimizing the proportion of nucleoside triphosphate monomers and extension reaction conditions, and a wide application prospect is provided for the fields of drug development, biosensor preparation and the like. A new path is opened up for research and application of the nucleic acid aptamer.

The invention provides a bispecific antibody targeting CD3 and tumor targets and application thereof. The bispecific antibody comprises a first antigen binding region, a second antigen binding region and an Fc part, the Fc part comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein of a first molecule or a fragment thereof, the binding protein of the first molecule or the fragment thereof is connected with the N end of the scFv fragment, and the C end of the scFv fragment is connected with the N end of the first Fc peptide fragment; the second antigen binding region comprises a binding protein of a second molecule or a fragment thereof, and the binding protein of the second molecule or the fragment thereof is connected with the N end of the second Fc peptide fragment; the first molecule and the second molecule are the same, and the scFv fragment has CD3 binding activity. The bispecific antibody is weak in combination with T cells, strong in combination with tumor cells, good in safety, high in anti-cancer activity and high in clinical application and drug development value.

The invention relates to the technical field of medicines, and provides a cyclic peptide compound, a pharmaceutical composition and application. The cyclopeptide compound provided by the invention has a structure as shown in a formula I. The cyclopeptide compound has remarkable EphA2 targeting affinity, has remarkable drug development potential on an EphA2 target spot, and has a wide application prospect in diagnosis, prevention and treatment of related diseases with high expression of EphA2. The result of the embodiment shows that the affinity constant KD of the cyclopeptide compound provided by the invention and an EphA2 target is between 1 * 10 <-9 > M and 1 * 10 <-7 > M, the cyclopeptide compound is difficult to dissociate after being combined with the target, and meanwhile, the cyclopeptide compound has very strong competitive capacity for a ligand Ephrin-A1 of the EphA2 target. # imgabs0 #